AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04689009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: current Standards Of Care
Description: The lesions will be cleansed with saline solution and, if necessary, surgical debridement will be performed with the most suitable method. At this point, if patient is included in EmoLED Group, the EmoLED treatment starts. After EmoLED application (EmoLED Group) or after cleansing (SOC Group), a polyurethane foam dressing will be applied on the lesion. In case of clinical signs of infection, a silver dressing will be applied.~Then an elasto-compressive double layer dressing of the limb with cohesive fixation bielastic latex-free bandage will be carried out.
Study NCT04689009 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: current Standards Of Care
Description: The lesions will be cleansed with saline solution and, if necessary, surgical debridement will be performed with the most suitable method. At this point, if patient is included in EmoLED Group, the EmoLED treatment starts. After EmoLED application (EmoLED Group) or after cleansing (SOC Group), a polyurethane foam dressing will be applied on the lesion. In case of clinical signs of infection, a silver dressing will be applied.~Then an elasto-compressive double layer dressing of the limb with cohesive fixation bielastic latex-free bandage will be carried out.
Study NCT03781336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based self care
Description: Experimental: an abridged mindfulness-based program that is incorporated into the work day, which consists of five weekly 1.5 hour sessions.
Study NCT01797926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC 5/100 amlodipine /losartan
Description: Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state
Study NCT03179449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic (ferumoxytol-enhanced MRI)
Description: Undergo ferumoxytol-enhanced MRI
Study NCT02348021 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous coronary intervention (PCI)
Study NCT03179449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Undergo surgical resection
Study NCT03179449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Given IV
Study NCT03179449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue Analysis
Description: Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
Study NCT04431414 — intervention group
Intervention type: OTHER
Intervention: Sample collection
Description: * blood, nasal swab, nasal wash, and saliva~* optional stool swab
Study NCT02348021 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dual Anti Platelet Therapy
Description: All patients will receive Dual Anti Platelet Therapy for one month
Study NCT01699919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lignocaine
Description: Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
Study NCT01699919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous lignocaine
Description: Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
Study NCT03637699 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Positive Psychology
Description: 5-week positive psychology intervention
Study NCT03015714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MIRT
Description: MIRT consists of a 4-week rehabilitation program in a hospital setting, which entails four daily sessions of physical therapy for five days and one hour of physical exercise on the sixth day. On the seventh day the patient rests. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with a physical therapist. The second session includes aerobic exercises to improve balance and gait, using different devices: a stabilometric platform with visual cues, a treadmill plus and a cycloergometer. The third session consists of occupational therapy, the fourth one includes one hour of speech therapy.
Study NCT03015714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MIRT-AT
Description: Patients in the MIRT-AT group will undergo the land-based therapy described in MIRT plus three sessions per week (Monday, Wednesday, Friday) of aquatic therapy. On days of aquatic therapy the first session of MIRT was not provided. The aquatic therapy program included aerobic exercises and physical activities to improve balance, motor skills, coordination and joints mobility. The water sessions were divided into 3 phases: i) Warm Up Exercises, ii) Central session Training, iii) Cool-down.
Study NCT03934749 — intervention group
Intervention type: DEVICE
Intervention: Non Invasive Ventilation
Description: NIV using standard mode or Lowenstein mode
Study NCT01784198 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein Intake
Description: Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Study NCT02390648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger
Description: Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
Study NCT02390648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
Study NCT01216098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doula support
Description: A doula is a paraprofessional who provides continuous emotional and physical support to women and their families during the intrapartum period.
Study NCT01413282 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac CT
Description: Calcium scan and CT coronary angiography
Study NCT01839370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop with Pramlintide
Description: A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
Study NCT03044145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Cultural Formulation Interview-Engagement Aid
Description: Culture affects how all people communicate and understand the world. Culture is important because patients and clinicians from different cultural backgrounds may have different preferences for communication. Mismatch in the clinician's approach and the patient's expectations of care can lead to patient dissatisfaction and discontinuation with treatment. Patients and clinicians may also have different views about what caused an illness, how it functions, what makes it better or worse, and the types of treatment needed. The CFI-EA is a series of questions over three sessions that clinicians can use to clarify patient views about treatment and communication so that patients stay in treatment longer. Clinicians can use the CFI-EA to customize their current treatment plans.
Study NCT00817830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lodenafil carbonate
Description: Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
Study NCT03956641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adaptated Physical Activity
Description: Evaluation of the physical condition and the quality of life during the course of treatment (after 8 weeks of treatment) and at the end of the treatment's line (except for breast cancer patients)
Study NCT03044145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Cultural Formulation Interview-Engagement Aid (Revised)
Description: The study team will revise the CFI-EA based on patient and clinician feedback. The study team expects that the revisions will consist of changes to the questions such as adding or subtracting specific items or revising the wording of the content. The study team do not anticipate other changes, though we will let our empirical data analyses guide revisions in consultation with the K23 mentor team.
Study NCT03044145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard mental health treatment at FHMC
Study NCT01831791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Description: Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
Study NCT04987372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The use of multimodal painkillers pre, per and postoperative
Study NCT04612426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain-computer Interface-Pedaling Training System
Description: The Brain-computer Interface-Pedaling Training System includes four parts: computer, monitor, EEG testing equipment and pedaling training equipment. The patient wears an EEG detection device, which calculates brain movement participation every 0.5 seconds. The system will provide real-time visual/auditory/somatosensory feedback to patients based on the results of participation, so that patients can participate in motor function training more attentively.
Study NCT04612426 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Traditional Pedaling Training System
Description: The patient will wear the same EEG equipment that will only collect data, but not guide training.
Study NCT04009148 — intervention group
Intervention type: OTHER
Intervention: CASCADE genetic screening
Description: Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
Study NCT04389697 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clear fluids and food up to up to 1 hour before the procedure
Description: Clear fluids and food up to up to 1 hour before the start of the procedure
Study NCT02030626 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: active or placebo rTMS or active or placebo tDCS
Study NCT02030626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active or placebo rTMS or active or placebo tDCS
Study NCT04520880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Testing procedure for Binding antibodies
Description: Levels of S-specific and N-specific binding antibodies will be measured by enzyme immune-sorbent assay (ELISA). Briefly, a purified, recombinant S or N proteins will be coated into 96-well plates and incubated for 1 hour at room temperature. The plates will be then washed with 1X PBS five times. The unbound regions of the coated S proteins are blocked by 5% non-fat dry milk. After overnight incubation at 4 C. The plates are washed several times with 5X PBS. Patients sera samples are added in duplicate and incubated for 1 hour at room temperature. After several washes. anti-human IgG HRP conjugate is added. After 1-hour incubation at room temperature, the plates are washed with 1X PBS five times 3,3', 5,5' tetramethylbenzidine (TMB) substrate is added to each wells and incubated for 5 minutes. The reaction will be then stopped with 0.2 M sulfuric acid and the absorbance is measured at 450nm.
Study NCT04520880 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neutralizing antibodies
Description: Neutralizing antibodies against the S protein of SARS-CoV-2 are measured by PV microneutralization assay. Briefly, individual plasmids expressing S.fl gene, luciferase genes, and reporter genes are co-transfected into 293T cells to produce luciferase-expressing pseudo-viruses. Then, pseudo-viruses are added at equal volume into 96 well plates and incubated at 37 for 1 hour. Then, the ACE2 expressing 293T cells are added into the 96well pates with 100 ul of patients' sera in duplicates. After, a single round of replication the cells are lysed with lysis buffer. Luciferase activity is measured by the luciferase assay kit. The activity of luciferases is proportional to the number of cells infected. Luciferase activity is then measured by the luminometer device and the neutralization rate is calculated.
Study NCT02397317 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multi-fraction SABR
Description: All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
Study NCT05329454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Tablets
Description: Treatment A:~One tablet of IBUMR will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBUMR every 12 hours for a total of 7 doses.~Treatment B:~One tablet of IBURed will be administered to the subjects under fasted condition, followed by a minimum of 72-hour washout interval. After the washout period, subjects will receive 1 × IBURed every 8 hours for a total of 10 doses.~Treatment C:~Single dose of IBUMR will be given to the subjects under fed condition (a standard high-fat, high calorie breakfast should be consumed within 30 minutes prior to dosing).
Study NCT02020824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to anxiogenous environments
Description: The anxiogenous environments are defined by several levels of possible anxiety classified progressively and independently by each patient at the beginning of the study. The exposure is applied during the 8 sessions for each of the arms Exposure to anxiogenous environments (with or without control).
Study NCT02020824 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to anxiogenous environments
Description: The anxiogenous environments are defined by several levels of possible anxiety classified progressively and independently by each patient at the beginning of the study. The exposure is applied during the 8 sessions for each of the arms Exposure to anxiogenous environments (with or without control).
Study NCT02020824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery with functional MRI initial
Description: Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
Study NCT02020824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imagery with functional MRI initial
Description: Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
Study NCT02020824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Imagery with functional MRI initial
Description: Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
Study NCT02020824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery with PET-scanner initial
Description: Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
Study NCT02020824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imagery with PET-scanner initial
Description: Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
Study NCT02020824 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Imagery with PET-scanner initial
Description: Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
Study NCT02020824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery with functional MRI final
Description: Patients will be submitted to 1 session of fMRI during a follow-up visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
Study NCT02020824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imagery with functional MRI final
Description: Patients will be submitted to 1 session of fMRI during a follow-up visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
Study NCT02020824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery with PET-scanner final
Description: Patients will be submitted to 1 session of PET-scanner during a follow-up visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
Study NCT02020824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Imagery with PET-scanner final
Description: Patients will be submitted to 1 session of PET-scanner during a follow-up visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
Study NCT03442413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-[18F]-FA PET/CT
Description: 2-\[18F\]FA is a highly specific radiotracer which has been used successfully to image nicotinic acetylcholine receptors in the human brain to characterize the effects of nicotine exposure (via smoking) on these receptors.
Study NCT03442413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.V. Nicotine
Description: Subjects in our study will receive intravenous nicotine at the adaptation session and each of the PET scans, close to the amount of nicotine absorbed from smoking 1/10 cigarette.
Study NCT01214746 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet Unikalk 1 time pr day for 5 days
Study NCT01214746 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Zarator, 80 mg pr day for 5 days
Study NCT01671969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: very low calorie diet
Description: medically supervised diet
Study NCT03679663 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Use of ultrasound to identify pre-puncture site
Study NCT00734786 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wrinkle cream application
Description: Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
Study NCT00849264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy with endostar
Description: 15mg/d×14d
Study NCT00849264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment with CBP and 5-FU
Description: CBP 300mg/d×2d，5-FU 1000mg/d×5d
Study NCT00849264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment with endostar, CBP and 5-FU
Description: CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
Study NCT04460690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid Onsite COVID-19 Detection
Description: saliva assay test for high concentrations of SARS-CoV-2
Study NCT03445858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
Study NCT03445858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Patients will receive decitabine every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.
Study NCT03445858 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Index Site Radiation
Description: Patients will receive a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions during the first cycle only.
Study NCT01912937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angioplasty treatment with the CVI Drug-coated Balloon (DCB)
Description: Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
Study NCT03428412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM and conventional drug
Description: All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The Experimental group will receive TCM according to the TCM syndrome. Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days.